How Smarteeva Enables Proactive Post-Market Surveillance with Real-World Data

Why Earlier Signal Detection Changes Everything

Three forces are converging to make reactive PMS untenable:

Recalls Are Getting More Expensive and More Public

A single Class I recall can cost tens of millions in direct remediation and far more in lost market share. The reputational damage compounds through social media and regulatory databases that are now searchable by anyone.

Device-Level Data Now Exists at Scale

Unique Device Identifiers (UDIs), cloud-connected sensors, and digitized service workflows create time-stamped, device-level records that simply did not exist ten years ago. The data is there. The question is whether your PMS system can use it.

Machine Learning Has Matured for Anomaly Detection

ML tools can flag outliers across thousands of product codes and geographies in seconds. PMS is no longer a quarterly retrospective. It can operate as near-real-time radar for safety signals.

‍

How Smarteeva Aligns with Regulatory Requirements for Real-World Evidence

Regulators are not just permitting proactive PMS. They are beginning to require it.

United States: FDA Real-World Evidence Guidance

The FDA’s Real-World Evidence Guidance (final, August 2017) establishes when real-world data can support regulatory decisions. The Medical Device Safety Action Plan pushes for a “robust patient-safety net” and earlier risk detection across the Total Product Life Cycle. The NEST (National Evaluation System for health Technology) initiative connects registries, EHRs, claims, and patient-generated data for active surveillance.

For medical device companies, this means internal data insights should be cross-checked with external industry or clinical trial data for validation. Smarteeva’s MDREngine aggregates global safety data, including FDA MAUDE records, to provide exactly this benchmarking capability.

European Union: MDR Articles 83-86

EU MDR Articles 83-86 make a continuous PMS system mandatory, along with annual and periodic safety update reports. The regulation explicitly calls for real-world data to refine risk profiles. Notified bodies will expect evidence that manufacturers trend field data and act on even subtle increases.

Smarteeva automates PSUR and PMSR generation, pulling from complaint records, investigation outcomes, and external safety data. The platform produces audit-ready reports in the formats regulators expect.

‍

How Early Signal Detection Could Have Changed Two Major Recalls

The value of proactive surveillance is clearest in hindsight.

Allergan Textured Breast Implants (2019)

Before the class, I recall that for BIA-ALCL risk, monthly Medical Device Reports (MDRs) jumped 131% between April and May. That surge was an unmistakable signal for anyone tracking the data. Pattern recognition at that stage could have triggered deeper investigation and potentially earlier field action.

Philips CPAP/BiPAP Ventilator Foam Degradation (2021)

More than 116,000 incident reports were logged and at least 561 deaths eventually linked to the devices. Spikes in MAUDE filings foreshadowed escalating risk months before the global recall.

In both cases, the data existed. The systems to act on it did not. Smarteeva’s AI-driven signal detection is built to flag these patterns automatically before they become recalls.

‍

How Smarteeva Implements a Proactive PMS Framework

Moving from reactive to proactive PMS requires five operational changes. Here is how Smarteeva addresses each one.

Step 1: Consolidate Every Data Stream

Fragmented data is the enemy of weak-signal detection. Smarteeva integrates complaint handling, field-service notes, regulatory submissions, and external safety databases into one platform. No more switching between systems to piece together a picture.

Step 2: Normalize and Enrich Records Automatically

Smarteeva uses UDIs, lot numbers, and geocodes to align records from different sources. The platform overlays utilization and install-base data so teams can calculate true incident rates, not just raw counts. A product with 50 complaints out of 10,000 units in the field tells a very different story than 50 complaints out of 500,000 units.

Step 3: Automate Signal Detection with AI

Smarteeva applies statistical process-control methods to low-volume products and machine-learning anomaly detection for high-volume portfolios where seasonality or geographic skew can mask trouble. The system sets adaptive thresholds. For example: alert when the incident-rate mean rises two standard deviations above the rolling 12-month baseline.

‍

PLATFORM STATS

96% first-pass extraction accuracy on incoming complaint data

95% duplicate detection rate (verified at Caldera Medical)

2.6M+ global safety records aggregated in MDREngine

‍

Step 4: Enable Cross-Functional Review, Not Just Reporting

Speed matters. The median time from first MDR surge to recall in public FDA data is still measured in years. Smarteeva surfaces flagged clusters so that quality, clinical, manufacturing, and service teams can review them together. The platform does not just generate reports. It creates the conditions for faster decisions.

Step 5: Close the Loop Visibly

Results from signal detection feed into design-change control, supplier corrective-action requests, and customer communications. Smarteeva maintains full traceability from signal to action, which satisfies both internal auditors and external regulators.

‍

How Proactive PMS Delivers ROI Beyond Risk Reduction

Cost Containment

Early field fixes (software patches, targeted component swaps) typically cost less than 10% of a global recall. Smarteeva’s automated signal detection catches problems at the stage where fixes are cheap, not after they have become Class I recalls.

Market Credibility

Proactive transparency builds trust with clinicians, payers, and patients. In digital-health categories where loyalty shifts fast, the manufacturer that demonstrates active safety monitoring earns a competitive advantage.

Faster Innovation Cycles

High-fidelity, real-world performance data shortens design cycles and supports evidence-based claims for next-generation devices. The same data that drives safety surveillance also drives product improvement.

‍

KEY METRICS

70% faster complaint resolution on the Smarteeva platform

8 min PSUR generation (replacing hours of manual work)

35% of all FDA MDRs filed through Smarteeva

‍

How to Start: Four Steps to Proactive PMS with Smarteeva

1. Audit Your Data Assets

Map where adverse events, complaints, service tickets, and user-generated feedback live today. Identify gaps and fragmentation points.

2. Pilot on One Product Family

Choose a device with a sufficient install base and recent field actions. Quick wins build executive support. Smarteeva implementations have gone from configuration to launch in as few as 2 weeks.

3. Layer in External Signals

Subscribe to FDA MAUDE/API feeds and EU vigilance databases. Smarteeva’s MDREngine already aggregates 2.6 million+ global safety records for benchmarking and cross-referencing against your internal data.

4. Document the Methodology from Day One

Align with FDA’s RWE guidance and EU MDR PMS expectations from the start. Smarteeva’s audit trails and compliance-ready outputs mean the documentation happens as part of the workflow, not as a separate project when auditors arrive.

‍

Closing

Manufacturers who treat PMS as a dynamic, ongoing function rather than a periodic obligation will identify risks earlier, reduce mitigation costs, and keep patient safety at the center of their operations. The data to do this already exists. The question is whether your system can act on it.

Smarteeva was built for exactly this purpose. One platform. AI-powered signal detection. Automated regulatory reporting. Global safety intelligence. Purpose-built for post-market surveillance.

‍